The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).
Tom Samuel Waddell
No relevant relationships to disclose
Ian Chau
Consultant or Advisory Role - Roche (U)
Honoraria - Roche
Research Funding - Roche
Yolanda Barbachano
No relevant relationships to disclose
David Gonzalez de Castro
No relevant relationships to disclose
Andrew Wotherspoon
No relevant relationships to disclose
Claire Saffery
No relevant relationships to disclose
Gary William Middleton
No relevant relationships to disclose
Jonathan Wadsley
No relevant relationships to disclose
David Raymond Ferry
No relevant relationships to disclose
Wasat Mansoor
No relevant relationships to disclose
Tom David Lewis Crosby
No relevant relationships to disclose
Fareeda Y Coxon
Research Funding - Roche
David Smith
No relevant relationships to disclose
Justin S. Waters
Consultant or Advisory Role - Roche (B)
Other Remuneration - Roche (B)
Timothy Iveson
Honoraria - Roche
Research Funding - Roche
Stephen Falk
No relevant relationships to disclose
Sarah Slater
No relevant relationships to disclose
Alicia Frances Clare Okines
Honoraria - Roche
David Cunningham
Consultant or Advisory Role - Amgen (U); Roche (U)
Research Funding - Amgen; Merck Serono; Roche
Expert Testimony - Amgen (U)